Metabolic disease in the Pacific: Lessons for indigenous populations
Author:
- 17 March 2022
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 45 (5) , 919-925
Abstract
Twenty-five percent of the New Zealand population is either Maori or Pacific and are thus indigenous to the region. The New Zealand National Metabolic Service has considerable experience in diagnosing and managing metabolic diseases in this population. The frequencies and phenotypes of inborn errors of metabolism in indigenous people differ from that in Western European populations. Metabolic services need to be aware of these local variations and adapt their screening and treatment protocols accordingly. Likewise, the services themselves need to adopt culturally appropriate practices. This includes an understanding of the language, ideally employment of indigenous people and targeting of the service to meet the needs of the people. Knowledge of the metabolic diseases common within particular ethnic groups is important for the rapid delivery of appropriate management. Newborn screening protocols need to reflect the local populations. With the advent of expanded newborn screening relatively benign forms of fatty acid oxidation disorders have been commonly encountered. This high prevalence may reflect a selective evolutionary advantage as similar conditions have been found in other ethnic groups with traditionally high fat and low carbohydrate diets. HLA haplotypes of indigenous populations are less represented in international stem cell transplant databanks thereby making the option of human stem cell transplant more challenging. The recent discovery that short-chain enoyl-CoA hydratase deficiency is particularly common in New Zealand with nearly a dozen cases identified this year suggests there is still a lot to learn regarding Maori and Pacific and indeed an indigenous metabolic disease.Keywords
This publication has 20 references indexed in Scilit:
- The natural history of elevated tetradecenoyl‐L‐carnitine detected by newborn screening in New Zealand: implications for very long chain acyl‐CoA dehydrogenase deficiency screening and treatmentJournal of Inherited Metabolic Disease, 2016
- A Founder Mutation in PET100 Causes Isolated Complex IV Deficiency in Lebanese Individuals with Leigh SyndromeThe American Journal of Human Genetics, 2014
- Primary Carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screeningJournal of Inherited Metabolic Disease, 2013
- Citrullinaemia type I: A common mutation in the Pacific Island populationJournal of Paediatrics and Child Health, 2011
- The paradox of the carnitine palmitoyltransferase type Ia P479L variant in Canadian Aboriginal populationsMolecular Genetics and Metabolism, 2009
- Reduced half-life of holocarboxylase synthetase from patients with severe Multiple Carboxylase DeficiencyHuman Mutation, 2008
- Cancer disparities in indigenous Polynesian populations: Māori, Native Hawaiians, and Pacific peopleThe Lancet Oncology, 2008
- Severe Holocarboxylase Synthetase Deficiency with Incomplete Biotin Responsiveness Resulting in Antenatal Insult in Samoan NeonatesThe Journal of Pediatrics, 2005
- Type I glutaric aciduria, part 1: Natural history of 77 patientsAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2003
- Feasibility of finding an unrelated bone marrow donor on international registries for New Zealand patientsBone Marrow Transplantation, 1999